Chronic kidney disease-associated pruritus – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:29:54 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Chronic kidney disease-associated pruritus – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Evaluation of MC2-25 Cream for Itching in Patients with Chronic Kidney Disease-associated Pruritus https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-mc2-25-cream-for-itchy-skin-in-chronic-kidney-disease-patients/ Wed, 29 Apr 2026 14:25:17 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-mc2-25-cream-for-itchy-skin-in-chronic-kidney-disease-patients/ This clinical trial aims to study the effectiveness and safety of MC2-25 cream compared to MC2-25 vehicle (the cream without the active ingredient) in treating chronic kidney disease-associated pruritus (CKD-aP). Pruritus refers to intense itching of the skin, which is a common and distressing symptom experienced by many people with chronic kidney disease. The condition can significantly impact quality of life and is often difficult to treat effectively with currently available options.

The purpose of the study is to determine if MC2-25 cream can reduce the severity of itching in adults who have kidney disease and suffer from persistent itching. The trial will last 12 weeks and will compare two groups of participants – one group will use the MC2-25 cream while the other will use the vehicle cream (placebo). Participants will need to record their itching intensity in a diary throughout the study period.

The study includes adult patients with moderate to severe itching who have chronic kidney disease stages G3-G5 (indicating moderate to severe kidney function impairment). Some participants may be receiving hemodialysis or hemodiafiltration, which are treatments that filter waste products from the blood when the kidneys can no longer perform this function adequately.

]]> Study on the Effectiveness and Safety of MC2-25 Cream for Itching in Chronic Kidney Disease Patients https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-mc2-25-cream-for-itching-in-chronic-kidney-disease-patients/ Wed, 29 Apr 2026 14:24:58 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-mc2-25-cream-for-itching-in-chronic-kidney-disease-patients/ This clinical trial is focused on studying a condition known as Chronic Kidney Disease-associated Pruritus (CKD-aP), which is a persistent itching that affects people with chronic kidney disease. The trial is testing a new treatment called MC2-25 cream, which contains the active ingredient alanyl glutamine. The study will compare the effects of this cream to a similar cream that does not contain the active ingredient, often referred to as a placebo.

The purpose of the study is to evaluate how effective and safe the MC2-25 cream is for people experiencing itching due to chronic kidney disease. Participants in the study will be randomly assigned to use either the MC2-25 cream or the placebo cream. The study will last for 12 weeks, during which participants will apply the cream to their skin as directed. Throughout the study, participants will be monitored to assess any changes in their symptoms and to ensure their safety.

This trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the MC2-25 cream and who is receiving the placebo. This approach helps to ensure that the results are unbiased and reliable. The main goal is to see if the MC2-25 cream can significantly reduce the itching experienced by participants compared to the placebo. Participants will be asked to keep a diary of their symptoms to help researchers measure the effectiveness of the treatment over the course of the study.

]]>